Back to Search Start Over

Outcomes of trabeculectomy with polyvinylpyrrolidone collagen versus mitomycin in primary open angle glaucoma. 36-month follow-up

Authors :
M. Alvarez-Padilla
P. Tolosa-Tort
Jesus Jimenez-Roman
F. Gil-Carrasco
A. Castillejos-Chevez
D. Alvarez-Ascencio
Source :
Archivos de la Sociedad Española de Oftalmología (English Edition). 96:202-209
Publication Year :
2021
Publisher :
Elsevier BV, 2021.

Abstract

Purpose Describe and compare the effects of intraoperative application of Polyvinylpyrrolidone Collagen (PVP) versus Mitomycin C (MMC) on the pattern of change in mean IOP reduction and mean number of medications over 36-months follow-up in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy. Methods Prospective, randomized, comparative study. Twenty-six eyes of 26 patients with POAG and no previous incisional glaucoma surgery underwent trabeculectomy and were randomized to PVP or MMC and completed a 36-month follow-up. Main outcome measures were IOP and number of glaucoma medications. Multivariate longitudinal analysis was performed by fitting a linear trend model adjusting for baseline response for the IOP outcome and a log-linear regression model with within-subject associations for the number of hypotensive medications outcome. Sensitivity analysis was performed to assess lower and higher order polynomial trends over time in IOP. Results The univariate analysis revealed that the mean IOP reduction from baseline to 36 months was 7.62 mmHg (3.05,12.18) in the MMC group and 8.15 mmHg (−0.64,16.95) in the PVP group. Mean percentage IOP reduction from baseline was 37.09% (15.93,58.17) and 36.08% (5.16,67.20) in the PVP group. Mean change in number of medications from baseline to 36 months was −0.92 medications (−3.38, +1.54)) for the MMC group and −1 medication (−3.12, +1.12). Both groups had a statistically significant decline in mean IOP over the follow-up period (p Conclusions The use of PVP during trabeculectomy achieves and maintains a statistically significant IOP reduction from baseline to 36 months and decreases the number of glaucoma medications. Secondary outcome measures showed a lower incidence of adverse events in the PVP group.

Details

ISSN :
21735794
Volume :
96
Database :
OpenAIRE
Journal :
Archivos de la Sociedad Española de Oftalmología (English Edition)
Accession number :
edsair.doi...........e5fbc2a4fba70b7a6b42a16fdc862002